# Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

> **NCT05576532** · PHASE2 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 30 (estimated)

## Conditions studied

- T-lymphoblastic Lymphoma
- Relapsed Disease
- Refractory Lymphoma
- Refractory Leukemia
- Safety
- Efficacy, Self

## Interventions

- **DRUG:** BCL2 Inhibitor plus IM2 regimen

## Key facts

- **NCT ID:** NCT05576532
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-10
- **Primary completion:** 2024-10-10
- **Final completion:** 2025-10-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576532, "Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05576532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*